A convenient method for the synthesis and purification of radioiodine-labeled diatrizoate and its derivatives is reported. The reaction conditions are well-suited for preparation of [ 123I]diatrizoate in “kit” form for routine use in nuclear medicine. Its use for clinical assessment of GFR will result in a major reduction in the radiation dose over standard urography and provide accurate diagnostic information not obtainable with other radiopharmaceuticals. Simultaneous determinations of GFR and ERPF are possible when [ 123I]diatrizoate is used in conjunction with [ 131I]orthoiodohippuran.
Read full abstract